Eales disease

From WikiMD's WELLNESSPEDIA


Eales disease
Synonyms Retinal periphlebitis, Primary retinal perivasculitis
Pronounce N/A
Specialty N/A
Symptoms Floaters, vision loss, photopsia
Complications Retinal detachment, vitreous hemorrhage
Onset Typically in young adults
Duration Chronic
Types N/A
Causes Unknown, possibly autoimmune
Risks Tuberculosis, genetic predisposition
Diagnosis Fluorescein angiography, Ophthalmoscopy
Differential diagnosis Diabetic retinopathy, Sarcoidosis, Behçet's disease
Prevention N/A
Treatment Corticosteroids, laser photocoagulation, vitrectomy
Medication N/A
Prognosis Variable, can lead to significant vision loss if untreated
Frequency Rare
Deaths N/A


Eales disease is an idiopathic, inflammatory condition that primarily affects the retina of the eye. It is characterized by recurrent episodes of retinal vasculitis, peripheral retinal ischemia, and neovascularization. The disease predominantly affects young adults, particularly males, and can lead to significant visual impairment if not managed appropriately.

Etiology[edit]

The exact cause of Eales disease remains unknown. However, it is believed to be associated with an abnormal immune response. Some studies suggest a possible link to tuberculosis due to the presence of Mycobacterium tuberculosis DNA in the ocular fluids of some patients.

Pathophysiology[edit]

Eales disease progresses through three stages:

  1. Inflammatory stage: Characterized by periphlebitis and retinal vasculitis.
  2. Ischemic stage: Marked by retinal ischemia and capillary non-perfusion.
  3. Proliferative stage: Involves neovascularization, which can lead to vitreous hemorrhage and tractional retinal detachment.

Clinical Features[edit]

Patients with Eales disease typically present with:

On examination, signs may include:

Diagnosis[edit]

Diagnosis is primarily clinical, supported by imaging studies such as:

Treatment[edit]

Management of Eales disease includes:

Prognosis[edit]

The prognosis of Eales disease varies. Early diagnosis and appropriate treatment can help preserve vision. However, complications such as recurrent vitreous hemorrhage and retinal detachment can lead to significant visual impairment.

Related Pages[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.